First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP)

被引：0
|
作者：
Ravaud, A.
Oudard, S.
Gravis-Mescam, G.
Sevin, E.
Zanetta, S.
Theodore, C.
de Fromont, M.
Oukhatar, C. Mahier-Ait
Chene, G.
Escudier, B.
机构：
[1] CHU Bordeaux, Hosp St Andre, Bordeaux, France
[2] Hop Europeen Georges Pompidou, Paris, France
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Ctr Francois Baclesse, F-14021 Caen, France
[5] Ctr Georges Francois Leclerc, Dijon, France
[6] Hop Foch, Suresnes, France
[7] FNCLCC, Paris, France
[8] ISPED, Bordeaux, France
[9] Inst Gustave Roussy, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5146
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    Motzer, R. J.
    Hutson, T. E.
    Olsen, M. R.
    Hudes, G. R.
    Burke, J. M.
    Edenfield, W. J.
    Wilding, G.
    Martell, B.
    Hariharan, S.
    Figlin, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [42] Phase I/II study of sunitinib malate in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Patel, P. H.
    Kondagunta, G. V.
    Redman, B. G.
    Hudes, G. R.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [44] Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma - A study of the National Cancer Institute of Canada Clinical Trials Group
    Shepherd, FA
    Dancey, J
    Arnold, A
    Neville, A
    Rusthoven, J
    Johnson, RD
    Fisher, B
    Eisenhauer, E
    CANCER, 2001, 92 (03) : 595 - 600
  • [45] Everolimus and sunitinib as first-and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Francais d'Etude des Tumeurs Uro-Genitales).
    Linassier, Claude
    Albiges, Laurence
    Chevreau, Christine
    Laguerre, Brigitte
    Oudard, Stephane
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Goldwasser, Francois
    Rolland, Frederic
    Delva, Remy
    Moise, Laura
    Tourani, Jean-Marc
    Vassal, Cecile
    Zanetta, Sylvie
    Penel, Nicolas
    Flechon, Aude
    Theodore, Christine
    Barthelemy, Philippe
    Saldana, Carolina
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial
    Broom, Reuben J.
    Hinder, Victoria
    Sharples, Katrina
    Proctor, Janie
    Duffey, Steven
    Pollard, Stephanie
    Fong, Peter C. C.
    Forgeson, Garry
    Harris, Dean L.
    Jameson, Michael B.
    O'Donnell, Anne
    North, Richard T.
    Deva, Sanjeev
    Hanning, Fritha J.
    Grey, Andrew
    Findlay, Michael P. N.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 50 - 58
  • [47] Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma
    Clark, PE
    Hall, MC
    Miller, A
    Ridenhour, KP
    Stindt, D
    Lovato, JF
    Patton, SE
    Brinkley, W
    Das, S
    Torti, FM
    UROLOGY, 2004, 63 (06) : 1061 - 1065
  • [48] Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: A phase II study of the genitourinary group of the French Federation of Cancer Centers
    Escudier, B
    Droz, JP
    Rolland, F
    Terrier-Lacombe, MJ
    Gravis, G
    Beuzeboc, P
    Chauvet, B
    Chevreau, C
    Eymard, JC
    Lesimple, T
    Merrouche, Y
    Oudard, S
    Priou, F
    Guillemare, C
    Gourgou, S
    Culine, S
    JOURNAL OF UROLOGY, 2002, 168 (03): : 959 - 961
  • [49] Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma
    Ceresoli, GL
    Dell'Oro, S
    Passoni, P
    Villa, E
    CANCER, 2000, 89 (01) : 89 - 96
  • [50] Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
    Feldman, Darren R.
    Ged, Yasser
    Lee, Chung-Han
    Knezevic, Andrea
    Molina, Ana M.
    Chen, Ying-Bei
    Chaim, Joshua
    Coskey, Devyn T.
    Murray, Samuel
    Tickoo, Satish K.
    Reuter, Victor E.
    Patil, Sujata
    Xiao, Han
    Aghalar, Jahan
    Apollo, Arlyn J.
    Carlo, Maria I.
    Motzer, Robert J.
    Voss, Martin H.
    CANCER, 2020, 126 (24) : 5247 - 5255
12345